bioXXmed Valuation

Is T5O undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of T5O when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate T5O's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate T5O's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for T5O?

Other financial metrics that can be useful for relative valuation.

T5O key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue294.2x
Enterprise Value/EBITDA-1.7x
PEG Ration/a

Price to Book Ratio vs Peers

How does T5O's PB Ratio compare to its peers?

The above table shows the PB ratio for T5O vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average14.7x
CNW co.don
1xn/a€6.5m
MDG1 Medigene
1.2x-4.1%€23.9m
HPHA Heidelberg Pharma
3.2x-33.0%€113.7m
VSC 4SC
53.4xn/a€58.0m
T5O bioXXmed
14.4xn/a€1.6m

Price-To-Book vs Peers: T5O is good value based on its Price-To-Book Ratio (14.4x) compared to the peer average (19.2x).


Price to Earnings Ratio vs Industry

How does T5O's PE Ratio compare vs other companies in the DE Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a39.5%
n/an/an/a
No. of CompaniesPB048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a39.5%
n/an/an/a
No more companies

Price-To-Book vs Industry: T5O is expensive based on its Price-To-Book Ratio (14.4x) compared to the European Biotechs industry average (2.4x).


Price to Book Ratio vs Fair Ratio

What is T5O's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

T5O PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio14.4x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate T5O's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies